Navigation Links
Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
Date:5/20/2009

NANTONG CITY, China, May 20 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to provide an update on the Company's progress to date this year and guidance on its projected financial performance for the balance of 2009.

Financial Highlights:

  • In Q1 2009, the Company's total revenue increased to RMB 4.60 million (US $0.68 million), representing a 127 percent increase year-over-year from the same period in 2008, when total sales were RMB 2.0 million (US $.29 million).
  • Also in Q1, the Company signed sales contracts for a total 1.5 millions units for Cisatracurium Besylate, Sinobiopharma's flagship drug, with business agents who distribute the Company's products in 30 provinces and key major cities throughout China. Total turnover is projected to be more than RMB 105 million (US $15.3 million), of which 70 percent will be Sinobiopharma profit.

Sales, Production and Marketing Highlights:

  • Sales of Cisatracurium Besylate increased by more than 200 percent from 2007 to 2008. Sales of 1.5 million units are projected in 2009. Sinobiopharma's patented formulation of Cisatracurium Besylate is now China's top-selling pre-surgical skeletal muscle relaxant.
  • Sales of Clindamycin, an antibiotic, increased by 150 percent from 2007 to 2008. Sales of 1 million units are projected in 2009.
  • The Company is currently in the process of launching in the domestic Chinese market. Sinobiopharma's formulation of this antihypertensive is the world's first in capsule form, making it easier to swallow. Sales of more than 500,000 capsules are projected in 2009. As the first Chinese maker of the latest generation of this drug, the Company's has multiple competitive advantages, including lower cost of active pharmaceutical ingredients (API), the ca
    '/>"/>

SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma Secures Rights to Seven Key Patents
7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
8. SemBioSys updates Apo AI development program
9. Strategic Diagnostics Updates Roth Conference Presentation Time
10. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
11. SGX Pharmaceuticals Updates Date of Presentation at the BIO InvestorForum 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... RICHMOND, Va., July 31 Insmed Inc. (Nasdaq: ... will host a conference call on Thursday, August 13(th), at ... second quarter 2009. Insmed intends to issue its quarterly ... 13(th). , , To participate in the ...
... LA JOLLA, Calif., July 30 TorreyPines Therapeutics, ... cancelled its Special Meeting of Stockholders, scheduled for today at 9:00 ... to vote upon a proposal to approve the liquidation and dissolution ... Plan of Merger by and between TPTX and Raptor Pharmaceuticals Corp., ...
... , , ... ("Senesco" or the "Company") (NYSE Amex: SNT ... entered into definitive purchase agreements with certain members of Senesco,s ... Company, which is the venture capital affiliate of Cato Research ...
Cached Biology Technology:Insmed to Host Second Quarter 2009 Conference Call 2TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 2TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 3TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 4Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 2Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 3Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 4Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 5
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... it has filed provisional patent 62/198989 for ... invention highlights a method to advance crypto-currencies such as ... introducing a common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... ANN ARBOR, Mich.---Vitamin A and beta-carotene supplements are ... boost the excretion of HIV in breast milk---thereby increasing ... a pair of new studies suggest. Epidemiologist Eduardo ... Health says transmission of HIV through breastfeeding happens because ...
... PHILADELPHIA - By comparing two species of ants, Shelley ... the University of Pennsylvania, and colleagues Danny Reinberg, PhD, ... University, have established an important new avenue of research ... or suppression of particular genes affects an organism,s characteristics, ...
... Colo. (August 26, 2010) The term "macrophage" conjures ... bacteria. However, macrophages do much more than that: Not ... play critical roles in immune regulation and wound-healing. They ... change their physiology in response to local cues. ...
Cached Biology News:Vitamin A increases the presence of the HIV virus in breast milk 2Genome comparison of ants establishes new model species for molecular research 2Genome comparison of ants establishes new model species for molecular research 3Genome comparison of ants establishes new model species for molecular research 4Macrophages: The 'defense' cells that help throughout the body 2Macrophages: The 'defense' cells that help throughout the body 3
EDG-6 (1)...
...
...
... Ab-1 stains tumor cells of embryonal carcinoma of ... germ cell tumors like seminoma. Glandular epithelium of ... Luminal and endocrine cells of stomach and acini ... also positive. Epitope: Carbohydrate portion on ...
Biology Products: